2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-101247
    MTPG 169209-66-9 98%
    MTPG is a potent mGluR2 and mGluR3 antagonist. MTPG can block the induction of brain ischemic tolerance induced by cerebral ischemic preconditioning. MTPG also significantly attenuates the inhibitory effect of L-CCG-1 on the KCl-evoked dopamine release.
    MTPG
  • HY-101260
    DORA-22 1088991-95-0 98%
    DORA-22 is an orally active dual orexinergic receptor antagonist, and improves the sleep disruption and memory impairment. DORA-22 can be used for study of insomnia.
    DORA-22
  • HY-101262
    SB234551 188257-69-4 98%
    SB234551 is a selective endothelin ETA receptor antagonist. SB234551 can be used in the study of stroke model.
    SB234551
  • HY-101290
    BMT-090605 1551403-51-0 98.27%
    BMT-090605 is a potent, selective the adapter protein-2 associated kinase 1 (AAK1) inhibitor with an IC50 value of 0.6 nM. BMT-090605 shows antinociceptive activity. BMT-090605 inhibits BMP-2-inducible protein kinase (BIKE) and Cyclin G-associated kinase (GAK) with IC50 values of 45 nM and 60 nM, respectively. BMT-090605 can be used for the research of neuropathic pain.
    BMT-090605
  • HY-101306
    Clocinnamox mesylate 117332-69-1 98%
    Clocinnamox (mesylate) is a potent opioid antagonist acting at mu, kappa and delta-receptors. Clocinnamox is a selective mu-receptor antagonist than kappa and delta-receptors.
    Clocinnamox mesylate
  • HY-101313
    (S)-Remoxipride 80125-14-0 98%
    (S)-Remoxipride ((-)-Remoxipride) is a selective dopamine D2-receptor antagonist with an IC50 value of 1.57 μM. (S)-Remoxipride can be used for the research of psychotic disorder.
    (S)-Remoxipride
  • HY-101314
    3-CPMT 14008-79-8 99.57%
    3-CPMT (Tropine 4-chlorobenzhydryl ether hydrochloride) is a potent dopamine uptake inhibitor. 3-CPMT (Tropine 4-chlorobenzhydryl ether hydrochloride) acts as a potent long-acting antihistaminic agent.
    3-CPMT
  • HY-101324
    MK-212 64022-27-1 98%
    MK-212 (CPP) is a centrally acting 5-HT1C/5-HT2 agonist. MK-212 can stimulate phosphoinositide hydrolysis in cerebral cortex.
    MK-212
  • HY-101332
    EGLU 170984-72-2 99.79%
    EGLU ((2S)-α-Ethylglutamic acid; (2S)-α-EGLU) is a potent and competitive mGluR-2 receptor antagonist. EGLU interacts with (lS,3S)-ACPD-sensitive site with a Kd value of 66 μM. EGLU is an antidepressant agent.
    EGLU
  • HY-101338
    RS-79948-197 186002-54-0 98%
    RS-79948-197 is a non-imidazoline α2-adrenoceptor antagonist. RS-79948-197 shows Kd values of 0.42 nM, 0.18 nM, 0.19 nM, 0.60 nM, 0.46 nM, and 0.77 nM for rat α2A, rat α2B, rat α2C, human α2A, human α2B, and human α2C, respectively.
    RS-79948-197
  • HY-101342
    RS 67506 hydrochloride 168986-61-6 98%
    RS 67506 hydrochloride is a 5-HT4 receptor agonist. The pKi value of RS 67506 hydrochloride for 5-HT4 in guinea pig striatum is 8.8. RS 67506 hydrochloride can be used in neuro-related research.
    RS 67506 hydrochloride
  • HY-101345
    AH 11110A 179388-65-9 98%
    AH 11110A is an α1B-adrenoceptor antagonist, but it can't effectively distinguish between the different subtypes of alpha(1) adrenoceptors (A, B, and D), nor can it clearly differentiate between alpha(1) and alpha(2) adrenoceptors.
    AH 11110A
  • HY-101349
    L 741742 156337-32-5 98%
    L 741742 is a dopamine receptor D4 (DRD4) antagonist that selectively inhibits glioblastomas (GBM) growth in vitro and in vivo, synergyed with Temozolomide (TMZ) (HY-17364). L 741742 disrupts in effectors PDGFRβ/ERK1/2 and mTOR signaling. Additionally, L 741742 disrupts endolysosmal function compromising the autophagy-lysosomal degradation pathway, followed by G0/G1 cell cycle arrest and Apoptosis. L 741742 is promising for research of GBM and neurogenesis.
    L 741742
  • HY-101357
    CP 93129 127792-75-0 98%
    CP 93129 is a potent and selective 5-HT1B agonist. CP 93129 has the potential for the research of Parkinson's disease.
    CP 93129
  • HY-101361
    Lidocaine methiodide 1462-71-1 98%
    Lidocaine methiodide (Methyllidocaine iodide) is a potent antiarrythmic agent, and is a derivative of Lidocaine (HY-B0185). Lidocaine methiodide can be used for the research of ventricular arrhythmias produced by coronary occlusion.
    Lidocaine methiodide
  • HY-101365
    RS-102221 185376-97-0 98%
    RS-102221 is a selective 5-HT2C receptor antagonist (Ki=10 nM). RS-102221 shows nearly 100-fold selectivity for the 5-HT2C receptor as compared to the 5-HT2A and 5-HT2B receptors. RS-102221 can promote the differentiation of new nerve cells. RS-102221 increases food-intake and weight-gain in rats.
    RS-102221
  • HY-101435
    Centpropazine 91315-34-3
    Centpropazine (CNPZ) is a brain-penetrant and non-selective antagonist of serotonin (5-HT1/5-HT2) and adrenergic (α1) receptors. Centpropazine functions by modulating monoamine neurotransmission, particularly reducing serotonin and norepinephrine reuptake, to exert antidepressant effects. Centpropazine is promising for research of depression.
    Centpropazine
  • HY-101480
    Xylamidine 6443-50-1 98%
    Xylamidine is a peripheral 5-HT receptor antagonist used to investigate possible peripheral appetite suppressant effects of 5-hydroxytryptophan (5-HTP) and fenfluramine. In a 1-hour food intake test, xylamidine attenuated the decrease in food intake induced by 5-HT and 5-HTP, but had no effect on fenfluramine, suggesting that the appetite suppressant effect of 5-HTP is mediated in part through peripheral 5-HT receptors. Microstructural analysis revealed that 5-HTP and fenfluramine induced a decrease in food intake rate and a reduction in feeding batch size. Xylamidine reversed the effects of 5-HTP on food intake rate and induced a slight increase in feeding batch size itself, thus, the peripheral effect of 5-HTP appears to be to slow food intake rate. No effect of xylamidine on fenfluramine-induced changes in feeding was observed. The results suggest that the appetite suppressant effects of 5-HTP and fenfluramine are differentiated based on the peripheral effects of 5-HTP. The peripheral effects of 5-HTP are distinct from the previously reported 5-HT-induced decreases in feeding batch size and duration. Possible mechanisms underlying the differences in peripheral effects of 5-HT and 5-HTP are discussed.
    Xylamidine
  • HY-101583
    NEO 376 496921-73-4 99.23%
    NEO 376 is a selective modulator of 5-HT1 receptor, GABA receptor and dopamine receptor, with anti-psychotic actively.
    NEO 376
  • HY-101653
    MHP 133 147340-43-0 98%
    MHP 133 is a agent with multiple CNS targets, and inhibits acetylcholinesterase (AChE) with Ki of 69 μM; also active against muscarinic M1 and M2 receptors, serotonin 5HT4 receptors, and imidazole I2 receptors.
    MHP 133
Cat. No. Product Name / Synonyms Application Reactivity